EE200300419A - R-(-)-N-metüül-3-[(2-metüül-4-hüdroksüfenüül)oksü]-3-fenüül-1-aminopropaan, seda sisaldav ravimpreparaat ning ühendi kasutamine norepinefriini ja serotoniini sissehaarde inhibiitorina - Google Patents

R-(-)-N-metüül-3-[(2-metüül-4-hüdroksüfenüül)oksü]-3-fenüül-1-aminopropaan, seda sisaldav ravimpreparaat ning ühendi kasutamine norepinefriini ja serotoniini sissehaarde inhibiitorina

Info

Publication number: EE200300419A
Authority: EE; Estonia
Prior art keywords: methyl; aminopropane; norepinephrine; hydroxyphenyl; oxy
Prior art date: 2001-03-06

Application number

EEP200300419A

Other languages

English (en)

Estonian (et)

Inventor

Louis Mattiuz Edward

Sauer John-Michael

Joe Wheeler William

Taiwai Wong David

Original Assignee

Eli Lilly And Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-06

Filing date

2002-02-20

Publication date

2004-02-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23045157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200300419(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-02-20 Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company

2004-02-16 Publication of EE200300419A publication Critical patent/EE200300419A/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Child & Adolescent Psychology (AREA)
Otolaryngology (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Anesthesiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EEP200300419A 2001-03-06 2002-02-20 R-(-)-N-metüül-3-[(2-metüül-4-hüdroksüfenüül)oksü]-3-fenüül-1-aminopropaan, seda sisaldav ravimpreparaat ning ühendi kasutamine norepinefriini ja serotoniini sissehaarde inhibiitorina EE200300419A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27373001P	2001-03-06	2001-03-06
PCT/US2002/003385 WO2002070457A1 (en)	2001-03-06	2002-02-20	Inhibitor of monoamine uptake

Publications (1)

Publication Number	Publication Date
EE200300419A true EE200300419A (et)	2004-02-16

Family

ID=23045157

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200300419A EE200300419A (et)	2001-03-06	2002-02-20	R-(-)-N-metüül-3-[(2-metüül-4-hüdroksüfenüül)oksü]-3-fenüül-1-aminopropaan, seda sisaldav ravimpreparaat ning ühendi kasutamine norepinefriini ja serotoniini sissehaarde inhibiitorina

Country Status (35)

Country	Link
US (2)	US20040082666A1 (da)
EP (1)	EP1379492B1 (da)
JP (1)	JP2004525912A (da)
KR (1)	KR20030092012A (da)
CN (1)	CN1229331C (da)
AP (1)	AP2003002855A0 (da)
AT (2)	ATE396170T1 (da)
AU (1)	AU2002245385B2 (da)
BR (1)	BR0207716A (da)
CA (1)	CA2440161A1 (da)
CH (1)	CH695982A5 (da)
CZ (1)	CZ20032380A3 (da)
DE (1)	DE60226715D1 (da)
DK (1)	DK200301267A (da)
EA (1)	EA005768B1 (da)
EC (1)	ECSP034760A (da)
EE (1)	EE200300419A (da)
ES (2)	ES2305221T3 (da)
FI (1)	FI20031191L (da)
GB (1)	GB2389851B (da)
HR (1)	HRP20030710A2 (da)
HU (1)	HUP0303341A3 (da)
IL (1)	IL157779A0 (da)
LT (1)	LT5143B (da)
LU (1)	LU91038B1 (da)
LV (1)	LV13119B (da)
NO (1)	NO20033921L (da)
NZ (1)	NZ527431A (da)
OA (1)	OA12494A (da)
PL (1)	PL363840A1 (da)
SE (1)	SE526598C2 (da)
SK (1)	SK10632003A3 (da)
TR (1)	TR200705146T1 (da)
WO (1)	WO2002070457A1 (da)
ZA (1)	ZA200306882B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60226715D1 (de) *	2001-03-06	2008-07-03	Lilly Co Eli	Monoamin-aufnahme-inhibitor
US20060241188A1 (en) *	2003-08-27	2006-10-26	Elililly And Company	Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors
CN1889940A (zh) *	2003-12-12	2007-01-03	伊莱利利公司	热潮红、冲动控制障碍和全身性医学病症引起的人格变化的治疗
WO2011027359A2 (en) *	2009-07-30	2011-03-10	Matrix Laboratories Ltd	Novel process for the preparation of 4-hydroxy atomoxetine
WO2012020418A1 (en)	2010-08-12	2012-02-16	Matrix Laboratories Ltd	Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
DE102013022397A1 (de)	2013-12-19	2016-07-07	Metrax Gmbh	Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage
GR1008819B (el)	2015-05-22	2016-08-01	Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων	Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
CN107935848B (zh) *	2017-11-21	2020-12-22	中国农业科学院兰州畜牧与兽药研究所	一种六茜素衍生物及其制备方法和应用
CA3117766A1 (en) *	2018-10-31	2020-05-07	Apnimed, Inc. (Delaware)	Methods and compositions for treating sleep apnea

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4018895A (en)	1974-01-10	1977-04-19	Eli Lilly And Company	Aryloxyphenylpropylamines in treating depression
US4314081A (en) *	1974-01-10	1982-02-02	Eli Lilly And Company	Arloxyphenylpropylamines
US4194009A (en)	1974-01-10	1980-03-18	Eli Lilly And Company	Aryloxyphenylpropylamines for obtaining a psychotropic effect
FR2432500A1 (fr) *	1978-02-24	1980-02-29	Roussel Uclaf	Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
US5112619A (en) *	1985-11-12	1992-05-12	Eli Lilly And Company	Orally administerable sustained release pharmaceutical formulation
US4956388A (en)	1986-12-22	1990-09-11	Eli Lilly And Company	3-aryloxy-3-substituted propanamines
ZA885824B (en) *	1987-08-14	1989-04-26	Merrell Dow Pharma	Novel antidepressants
PH30083A (en) *	1991-02-25	1996-12-27	Lilly Co Eli	Treatment of lower urinary tract disorders
TW514634B (en)	1997-10-14	2002-12-21	Lilly Co Eli	Process to make chiral compounds
AU3219800A (en)	1999-03-29	2000-10-16	Eli Lilly And Company	Stereospecific method for preparing tomoxetine and intermediates thereof
JP2002541235A (ja)	1999-04-09	2002-12-03	イーライ・リリー・アンド・カンパニー	３−アリールオキシ−３−アリールプロピルアミン及びその中間体の製造方法
EP1395253A2 (en) *	2000-11-15	2004-03-10	Eli Lilly And Company	Treatment of anxiety disorders
DE60226715D1 (de) *	2001-03-06	2008-07-03	Lilly Co Eli	Monoamin-aufnahme-inhibitor

2002
- 2002-02-20 DE DE60226715T patent/DE60226715D1/de not_active Revoked
- 2002-02-20 AT AT02713538T patent/ATE396170T1/de not_active IP Right Cessation
- 2002-02-20 CN CNB028060253A patent/CN1229331C/zh not_active Ceased
- 2002-02-20 KR KR10-2003-7011635A patent/KR20030092012A/ko not_active Ceased
- 2002-02-20 GB GB0323169A patent/GB2389851B/en not_active Expired - Fee Related
- 2002-02-20 IL IL15777902A patent/IL157779A0/xx unknown
- 2002-02-20 TR TR2007/05146T patent/TR200705146T1/xx unknown
- 2002-02-20 AT AT0904202A patent/AT414238B/de not_active IP Right Cessation
- 2002-02-20 BR BR0207716-7A patent/BR0207716A/pt not_active IP Right Cessation
- 2002-02-20 WO PCT/US2002/003385 patent/WO2002070457A1/en not_active Ceased
- 2002-02-20 LU LU91038A patent/LU91038B1/fr active
- 2002-02-20 ES ES02713538T patent/ES2305221T3/es not_active Expired - Lifetime
- 2002-02-20 HU HU0303341A patent/HUP0303341A3/hu unknown
- 2002-02-20 HR HR20030710A patent/HRP20030710A2/hr not_active Application Discontinuation
- 2002-02-20 OA OA1200300215A patent/OA12494A/en unknown
- 2002-02-20 EE EEP200300419A patent/EE200300419A/xx unknown
- 2002-02-20 AP APAP/P/2003/002855A patent/AP2003002855A0/en unknown
- 2002-02-20 FI FI20031191A patent/FI20031191L/fi not_active IP Right Cessation
- 2002-02-20 CA CA002440161A patent/CA2440161A1/en not_active Abandoned
- 2002-02-20 SK SK1063-2003A patent/SK10632003A3/sk unknown
- 2002-02-20 EA EA200300978A patent/EA005768B1/ru not_active IP Right Cessation
- 2002-02-20 CH CH01522/03A patent/CH695982A5/de not_active IP Right Cessation
- 2002-02-20 ES ES200350052A patent/ES2201942B2/es not_active Expired - Fee Related
- 2002-02-20 EP EP02713538A patent/EP1379492B1/en not_active Revoked
- 2002-02-20 US US10/468,553 patent/US20040082666A1/en not_active Abandoned
- 2002-02-20 JP JP2002569778A patent/JP2004525912A/ja not_active Ceased
- 2002-02-20 CZ CZ20032380A patent/CZ20032380A3/cs unknown
- 2002-02-20 AU AU2002245385A patent/AU2002245385B2/en not_active Ceased
- 2002-02-20 NZ NZ527431A patent/NZ527431A/en unknown
- 2002-02-20 PL PL02363840A patent/PL363840A1/xx not_active Application Discontinuation
2003
- 2003-08-11 LT LT2003075A patent/LT5143B/lt unknown
- 2003-09-02 EC EC2003004760A patent/ECSP034760A/es unknown
- 2003-09-03 SE SE0302361A patent/SE526598C2/sv not_active IP Right Cessation
- 2003-09-03 ZA ZA200306882A patent/ZA200306882B/en unknown
- 2003-09-04 NO NO20033921A patent/NO20033921L/no not_active Application Discontinuation
- 2003-09-04 DK DK200301267A patent/DK200301267A/da not_active Application Discontinuation
- 2003-09-10 LV LVP-03-100A patent/LV13119B/en unknown
2005
- 2005-05-09 US US11/125,348 patent/US7384983B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN1229331C (zh)	2005-11-30
SE526598C2 (sv)	2005-10-18
CH695982A5 (de)	2006-11-15
SE0302361D0 (sv)	2003-09-03
FI20031191A7 (fi)	2003-08-25
CA2440161A1 (en)	2002-09-12
FI20031191L (fi)	2003-08-25
HUP0303341A3 (en)	2007-03-28
HUP0303341A2 (hu)	2004-01-28
IL157779A0 (en)	2004-03-28
WO2002070457A1 (en)	2002-09-12
LU91038B1 (fr)	2003-09-11
GB2389851A (en)	2003-12-24
TR200705146T1 (tr)	2008-02-21
AT414238B (de)	2006-10-15
EA200300978A1 (ru)	2004-02-26
GB0323169D0 (en)	2003-11-05
KR20030092012A (ko)	2003-12-03
LT2003075A (en)	2004-03-25
WO2002070457A8 (en)	2004-06-03
PL363840A1 (pl)	2004-11-29
BR0207716A (pt)	2004-03-23
NO20033921L (no)	2003-11-05
GB2389851B (en)	2005-05-25
OA12494A (en)	2006-05-24
ES2305221T3 (es)	2008-11-01
LT5143B (lt)	2004-06-25
ES2201942B2 (es)	2004-12-16
AP2003002855A0 (en)	2003-08-20
HRP20030710A2 (en)	2004-08-31
ZA200306882B (en)	2004-12-03
EP1379492B1 (en)	2008-05-21
SE0302361L (sv)	2003-09-03
EP1379492A1 (en)	2004-01-14
EA005768B1 (ru)	2005-06-30
DK200301267A (da)	2003-11-06
NO20033921D0 (no)	2003-09-04
ATE396170T1 (de)	2008-06-15
US20050209341A1 (en)	2005-09-22
JP2004525912A (ja)	2004-08-26
ECSP034760A (es)	2003-10-28
LV13119B (en)	2004-06-20
DE60226715D1 (de)	2008-07-03
ES2201942A1 (es)	2004-03-16
CZ20032380A3 (en)	2004-03-17
ATA90422002A (de)	2006-01-15
NZ527431A (en)	2005-05-27
US20040082666A1 (en)	2004-04-29
AU2002245385B2 (en)	2007-01-18
US7384983B2 (en)	2008-06-10
CN1494526A (zh)	2004-05-05
SK10632003A3 (sk)	2004-06-08

Publication	Publication Date	Title
EE05475B1 (et)	2011-10-17	Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon
ATE307571T1 (de)	2005-11-15	Pharmazeutische formulierung enthaltend bicalutamid
ATE334656T1 (de)	2006-08-15	Flüssige pharmazeutische zusammensetzung
NO20033384D0 (no)	2003-07-29	Farmasöytisk formulering
EE05378B1 (et)	2011-02-15	LahustuvaÁCTLA4ÁsulandmolekuliÁkasutamineÁravimkoostiseÁvalmistamiseks
FI20011478L (fi)	2003-01-06	Farmaseuttinen koostumus
NO20025450L (no)	2002-11-14	Ny farmasöytisk sammensetning
DE60142197D1 (de)	2010-07-01	Pharmazeutische Zusammensetzung
ITTO20010008A0 (it)	2001-01-10	Formulazione farmaceutica
AT7729U3 (de)	2006-01-15	Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
SI1407008T1 (sl)	2009-06-30	Sestavek influenčne vakcine
NO20035627D0 (no)	2003-12-15	Farmasöytisk formulering
NO20040254L (no)	2004-03-22	Farmasoytiske sammensetninger som inneholder terbinafin og anvendelse derav
FI20022128A0 (fi)	2002-12-03	Farmaseuttinen koostumus
DE60211183D1 (de)	2006-06-08	Pharmazeutische zusammensetzung enthaltend lumiracoxib
ATE350016T1 (de)	2007-01-15	Bicalutamid enthaltende pharmazeutische zusammensetzung
ATE366128T1 (de)	2007-07-15	Pharmazeutische zusammensetzung
NO20041485L (no)	2004-04-13	Farmasoytisk formulering omfattende (R)-bicalutamid
EE200200480A (et)	2004-02-16	Memnopeptiidühend, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
DE10291905D2 (de)	2004-05-27	Pharmazeutische Zusammensetzung
ATE350029T1 (de)	2007-01-15	Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
DE10107261B4 (de)	2005-03-10	Pharmazeutische Zusammensetzung
NO20041236L (no)	2004-03-24	Farmasoytisk formulering
SE0101171D0 (sv)	2001-04-02	Pharmaceutical formulation
SE0103565D0 (sv)	2001-10-25	Pharmaceutical formulation